News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
FDA
EU Backs Nycomed’s Daxas In Deadly Lung Disease; Drug Approval Could Spur Nycomed IPO
July 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH July 6 (Reuters) - Nycomed's [NYCMD.UL] lung drug Daxas has won European Union backing to treat patients with chronic obstructive pulmonary disease, bringing to market the first new type of treatment for the disease in over a decade.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Artificial intelligence
Amid Layoffs, Delays, FDA Turns to AI for Speedy Reviews
May 9, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Delays Continue as Regulator Misses Review Date for GSK’s Nucala
May 9, 2025
·
2 min read
·
Tristan Manalac
Special edition
Deep Dive: Biopharma In Turmoil As Peter Marks Forced Out of FDA
May 9, 2025
·
2 min read
·
Annalee Armstrong
Job Trends
Job Market Woes: More Funding, Stability Needed for Turnaround
May 8, 2025
·
5 min read
·
Angela Gabriel